Company Filing History:
2 out of 559 
1 out of 504 
Years Active: 2021
Title: Paul Jeng: Innovator in Proliferative Disease Treatment
Introduction
Paul Jeng is a notable inventor based in New Rochelle, NY (US), recognized for his contributions to the field of medicine, particularly in the treatment of proliferative diseases. With a total of 2 patents to his name, Jeng has made significant strides in developing innovative pharmaceutical compositions.
Latest Patents
Jeng's latest patents focus on phenylsulfonamido-benzofuran derivatives and their uses in treating proliferative diseases. These derivatives, along with their pharmaceutically acceptable salts, are designed to inhibit proteins of the BCL-2 family, which play a crucial role in the progression of various diseases, including cancers, inflammatory diseases, and autoimmune diseases. The compounds described in his patents are selective inhibitors of MCL-1, a member of the BCL-2 family, providing a targeted approach to treatment.
Career Highlights
Throughout his career, Paul Jeng has worked with prestigious institutions such as Memorial Sloan Kettering Cancer Center and Albert Einstein College of Medicine. His work in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of Jeng's notable coworkers include Emily H Cheng and Ouathek Ouerfelli. Their collaborative efforts have further advanced the research and development of innovative treatments for proliferative diseases.
Conclusion
Paul Jeng's work exemplifies the impact of innovation in the medical field, particularly in the fight against proliferative diseases. His patents and collaborations highlight the importance of targeted therapies in improving patient outcomes.